Evidence map›Paper›PMID 42572097›Full record

ArticleInternational urology and nephrology2026

Incident chronic kidney disease risk and the predictive value of the uric acid-to-HDL ratio in lean and non-lean MASLD: a prospective cohort and multi-omics study.

Yuting Zhang, Shurong Liu, Zijian Huang, Shuting Song, Shengjia Xu, Chaofeng Guan, Yajing Chen, Ming Song, Peilin Pang, Wenrun Wu and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yuting ZhangDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shurong LiuThe Third People's Hospital of Longgang, Clinical Institute of Shantou University Medical College (The Third People's Hospital of Longgang District Shenzhen)/Longgang Institute of Medical Imaging, Shantou University Medical College and The Third People's Hospital of Longgang District, Shenzhen, China.
Zijian HuangDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shuting SongDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shengjia XuDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Chaofeng GuanSchool of Public Health, Hubei University of Medicine, Shiyan, China.
Yajing ChenPostgraduate Training Base at Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, China.
Ming SongDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Peilin PangDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wenrun WuDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Sailun WangDepartment of Internal Medicine, Institute for Lung Health (ILH), Member of the German Center for Lung Research (DZL), Member of the Excellence Cluster Cardio-Pulmonary Institute (CPI), Justus Liebig University, Giessen, Germany.
Xiaoli ChenDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Lin ZhangDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Liang ZhengDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Qian ZhaoDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Baktybek KojonazarovDepartment of Internal Medicine, Institute for Lung Health (ILH), Member of the German Center for Lung Research (DZL), Member of the Excellence Cluster Cardio-Pulmonary Institute (CPI), Justus Liebig University, Giessen, Germany.
Yuzhen ZhangDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jie LiuDepartment of Cardiovascular Surgery State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. kenliujie@126.com.ORCID https://orcid.org/0000-0002-9476-1833
Gang ZhaoCenter of Gallstone Disease, Shanghai East Hospital, Tongji University School of Medicine, Institution of Gallstone Disease, Shanghai, China. zhao_gang7@vip.163.com.

Funding

National Key Research and Development Program of China 2022YFA1104503National Natural Science Foundation of China 82130016, 82570511, 82270260, 82170257National Science and Technology Major Project 2026ZD0554402
6 · The paper itself

Abstract

backgroundAlthough metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for chronic kidney disease (CKD), validated clinical markers for individualized renal risk stratification remain limited, especially in lean patients. Therefore, we aimed to evaluate an accessible index to predict this risk and explore the underlying pathophysiological mechanisms.

methodsWe investigated incident CKD risk among UK Biobank participants across a biomarker-based FLI cohort (N = 353,325) and an imaging-based MRI-PDFF cohort (N = 33,155). The participants with MASLD were stratified into lean and non-lean groups. We then evaluated uric acid to HDL ratio (UHR) as a continuous proxy to assess metabolic-related renal risk, and integrated Mendelian randomization (MR), plasma proteomics, and single-cell RNA sequencing to identify circulating mediators.

resultsWhile non-lean MASLD consistently increased CKD risk, the risk in lean MASLD differed by metabolic status. FLI-defined lean MASLD, characterized by severe metabolic abnormalities, predicted a higher incident CKD risk, whereas MRI-defined lean MASLD with milder metabolic traits showed no such association. Furthermore, UHR showed a dose-response relationship with CKD and provided better predictive value than the TyG index. MR analyses revealed that MASLD increases CKD risk indirectly through metabolic burden. Integrative multi-omics analyses suggested AHSG and CPB2 as potential circulating markers of this metabolic-renal axis.

conclusionsIn MASLD, the severity of systemic metabolic burden is a key determinant of incident CKD risk across both lean and non-lean individuals. To quantify this burden, UHR serves as a robust continuous proxy that provides better renal risk stratification than the TyG index for both lean and non-lean patients. Furthermore, AHSG and CPB2 represent potential circulating biomarkers for this metabolic-renal link.

Indexed as

Chronic kidney diseaseLean MASLDMetabolic dysfunction-associated steatotic liver diseaseRisk stratificationUric acid-to-HDL ratio

Identifiers

PMID42572097

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.